BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Glypican-3
1
Targeting glypican-3 as a new frontier in liver cancer therapy
9/25/2025 11:24:01 AM | Browse: 129 | Download: 109
2
Bi-specific T1 positive-contrast-enhanced magnetic resonance imaging molecular probe for hepatocellular carcinoma in an orthotopic mouse model
4/15/2022 9:40:09 AM | Browse: 671 | Download: 2462
3
Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization
8/25/2020 9:45:46 AM | Browse: 938 | Download: 1999
4
Novel molecular targets in hepatocellular carcinoma
8/21/2020 1:38:19 AM | Browse: 932 | Download: 1819
5
Development and in vitro study of bi-specific magnetic resonance imaging molecular probe for hepatocellular carcinoma
6/28/2019 12:22:27 PM | Browse: 1164 | Download: 2396
6
Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma
3/31/2019 7:22:50 AM | Browse: 1173 | Download: 1989
7
Positron emission tomography combined with computed tomography finding: Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
1/26/2018 2:31:05 AM | Browse: 1162 | Download: 2248
8
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
12/31/2015 1:27:00 PM | Browse: 1413 | Download: 2493
9
Biomarkers for the early diagnosis of hepatocellular carcinoma
9/28/2015 6:06:00 PM | Browse: 1526 | Download: 2400
10
Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: A meta-analysis
8/26/2014 5:16:00 PM | Browse: 1177 | Download: 1194
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345